1. Search Result
Search Result
Results for "

AurkA

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Recombinant Proteins

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137344A

    PROTACs Aurora Kinase Cancer
    dAURK-4 hydrochloride, an Alisertib (HY-10971) derivative, is a potent and selective PROTAC AURKA (Aurora A) degrader. dAURK-4 hydrochloride has anticancer effects. (Pink: Ligand for target protein (HY-10971); Black: Linker (HY-W004640); Blue: Ligand for E3 ligase Thalidomide-O-COOH (HY-103597)) .
    dAURK-4 hydrochloride
  • HY-112273

    Aurora Kinase Cancer
    CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer .
    CD532
  • HY-161407

    Aurora Kinase Cancer
    AURKA-IN-1 (compound 9) is an cell-active covalent AURKA inhibitor. AURKA-IN-1 is a lysine-reactive activity probe .
    AURKA-IN-1
  • HY-158038

    Aurora Kinase Cancer
    AurkA allosteric-IN-1 (compound 6h) is an Aurora A (AurkA) inhibitor (IC50: 6.50 μM) that inhibits the catalytic activity and non-catalytic functions of Aurora A. Aurora A regulates the assembly of the bipolar mitotic spindle and the fidelity of chromosome segregation during mitosis and has non-catalytic functions. AurkA allosteric-IN-1 blocks the interaction of AurkA with the activator TPX2 by binding to the Y pocket of AurkA .
    AurkA allosteric-IN-1
  • HY-162837

    Aurora Kinase Cancer
    AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3 .
    AURKA against 1
  • HY-RS01266

    Small Interfering RNA (siRNA) Others

    AURKA Human Pre-designed siRNA Set A contains three designed siRNAs for AURKA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AURKA Human Pre-designed siRNA Set A
    AURKA Human Pre-designed siRNA Set A
  • HY-RS01267

    Small Interfering RNA (siRNA) Others

    Aurka Mouse Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Aurka Mouse Pre-designed siRNA Set A
    Aurka Mouse Pre-designed siRNA Set A
  • HY-RS01268

    Small Interfering RNA (siRNA) Others

    Aurka Rat Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Aurka Rat Pre-designed siRNA Set A
    Aurka Rat Pre-designed siRNA Set A
  • HY-155464

    VEGFR Aurora Kinase Cancer
    VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC50: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential .
    VEGFR-2/AURKA-IN-1
  • HY-137344

    PROTACs Aurora Kinase Cancer
    dAURK-4, an Alisertib (HY-10971) derivative, is a potent and selective AURKA (Aurora A) degrader. dAURK-4 has anticancer effects .
    dAURK-4
  • HY-112273A

    Aurora Kinase Cancer
    CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer .
    CD532 hydrochloride
  • HY-168543

    PROTACs Aurora Kinase Mps1 Cancer
    PROTAC MPS1 degrader 2 (Compound 15) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA and AURKB, with DC50s of 42.0, 2.1 and 154.0 nM, respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168545); Black: linker (HY-N0420); Blue: ligand for E3 ligase (HY-10984) .
    PROTAC MPS1 degrader 2
  • HY-168540

    PROTACs Mps1 Aurora Kinase Cancer
    PROTAC MPS1 degrader 1 (Compound 19) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA and AURKB, with DC50s of 17.7, 108.7 and 570.3 nM, respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168542); Black: linker (HY-W141926); Blue: ligand for E3 ligase (HY-10984) .
    PROTAC MPS1 degrader 1
  • HY-100865

    DBPR114

    FLT3 Cancer
    BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy .
    BPR1K871
  • HY-148065

    PROTACs Cancer
    FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
    FMF-06-098-1
  • HY-157396

    Aurora Kinase Apoptosis Cancer
    JAB-2485 is a potent and selective Aurora kinase A (AURKA) inhibitor, with an IC50 of 0.33 nM. JAB-2485 exhibits around 1700-fold selectivity for AURKA over AURKB. JAB-2485 induces cell cycle arrest and apoptosis. JAB-2485 can be used for the research of cancer .
    JAB-2485
  • HY-162469

    Aurora Kinase c-Myc Cancer
    6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity .
    6K465
  • HY-125956

    Aurora Kinase Cancer
    Aurkin A is an allosteric inhibitor for the interaction between Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with Kd of 3.77 μM .
    Aurkin A
  • HY-147703

    Aurora Kinase Cancer
    Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC50s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .
    Aurora kinase inhibitor-9
  • HY-103645

    Bacterial Aurora Kinase Apoptosis Infection Cancer
    GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway . MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
    GW779439X
  • HY-125090

    Aurora Kinase c-Myc Bcr-Abl Histone Methyltransferase Apoptosis Cancer
    PHA-680626 is an effective inhibitor of the interaction between Aurora-A and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463)-resistant chronic myeloid leukemia cell lines and primary CD34+ cells .
    PHA-680626

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: